Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1995-05-08
2000-12-05
Allen, Marianne P.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241921, 4242771, 435 71, 435 724, 435325, 435366, 514 2, 514 12, 514 13, 514 14, 514 15, 530324, 530325, 530326, 530327, 530328, A61K 3900, C07K 700
Patent
active
061563161
ABSTRACT:
Fusion-point spanning peptides, for example BCR-ABL fusion breakpoint peptides associated with chronic myelogenous leukemia (CML), bind major histompatibility complex molecules, such as HLA class I molecules, and induce cytotoxic T cell proliferation. The breakpoint peptides can be used as vaccines.
REFERENCES:
patent: 5320947 (1994-06-01), Cheever et al.
patent: 5961978 (1999-10-01), Gaudernack et al.
Chen, et al., Proc. Natl. Acad. Sci. USA (1992) 89:1468-1472.
Cullis, et al., Leukemia (1994) 8:165-170.
Cellis, et al., Proc. Natl. Acad. Sci. USA (1994) 91:2105-2109.
Gambacorti-Passerini, et al., Blood (1994) 84(Supp. 1):618a, abstract no. 2459.
Drexler, et al., Leukemia (1995) 9:480-500.
Bocchia, et al., Blood (May 15, 1995) 85:2680-2684.
Bocchia Monica
Scheinberg David A.
Sette Alessandro
Allen Marianne P.
Cytel Corporation
Sloan-Kettering Institute for Cancer Research
White John P.
LandOfFree
Oncogene fusion protein peptide vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oncogene fusion protein peptide vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oncogene fusion protein peptide vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-958957